132
Participants
Start Date
December 7, 2022
Primary Completion Date
December 30, 2024
Study Completion Date
December 30, 2024
Low Dose Recombinant Herpes Zoster Vaccine (CHO cells)
0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with low dose MA105.
High Dose Recombinant Herpes Zoster Vaccine (CHO cells)
0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with high dose MA105.
Low dose adjuvant
0.5 mL per dose, containing low dose MA105 adjuvant.
High dose adjuvant
0.5 mL per dose, containing high dose MA105 adjuvant.
Positive control
0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with AS01B.
Placebo
0.5 mL per dose, containing 4.5 mg sodium chloride.
Yanjin District Center for Disease Control and Prevention, Xinxiang
Lead Sponsor
Henan Center for Disease Control and Prevention
OTHER_GOV
MAXVAX Biotechnology Limited Liability Company
INDUSTRY